These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22183797)

  • 21. The role of the epidermal growth factor receptor in breast cancer.
    Chan SK; Hill ME; Gullick WJ
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):3-11. PubMed ID: 16947082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
    Moulder SL
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of HER-2 inhibitors.
    Rabindran SK
    Cancer Lett; 2005 Sep; 227(1):9-23. PubMed ID: 16051028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into anti-HER-2 receptor monoclonal antibody research.
    Kumar R; Mandal M; Vadlamudi R
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New agents in development for breast cancer.
    Gao XP; Liu F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Her-2/neu in breast cancer: as easy as this!
    Azim H; Azim HA
    Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HER receptor family: a rich target for therapeutic development.
    Mass RD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):932-40. PubMed ID: 14967453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 35. [Targeting epidermal growth factor receptor in cancer of the breast].
    Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
    Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
    Raben D; Bianco C; Helfrich B; Weng E; Ciardiello F; Harari P
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):461-71. PubMed ID: 12647989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Resistant mechanisms against breast cancer treatment and therapeutic strategies].
    Tanizaki J; Tsurutani J
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():336-40. PubMed ID: 23513862
    [No Abstract]   [Full Text] [Related]  

  • 38. [Breast cancer and Her-2].
    Hatake K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144
    [No Abstract]   [Full Text] [Related]  

  • 39. [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
    Magné N; Milano G
    Bull Cancer; 2004 Dec; 91 Suppl 4():S257-60. PubMed ID: 15899618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecularly targeted therapeutics for breast cancer.
    Hussain SA; Palmer DH; Spooner D; Rea DW
    BioDrugs; 2007; 21(4):215-24. PubMed ID: 17628119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.